{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:17:24Z","timestamp":1790083044294,"version":"4.0.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s11899-021-00615-7","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T14:02:45Z","timestamp":1614261765000},"page":"32-39","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies"],"prefix":"10.1007","volume":"16","author":[{"given":"Taha","family":"Al-Juhaishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"615_CR1","unstructured":"Cancer Stat Facts: Non-Hodgkin lymphoma [Internet]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html. Accessed Dec 2020."},{"key":"615_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11899-019-00518-8","volume":"14","author":"M Kesavan","year":"2019","unstructured":"Kesavan M, Eyre TA, Collins GP. Front-line treatment of high grade B cell non-Hodgkin lymphoma. Curr Hematol Malig Rep. 2019;14:207\u201318.","journal-title":"Curr Hematol Malig Rep"},{"key":"615_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ajh.25696","volume":"95","author":"A Freedman","year":"2020","unstructured":"Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95:316\u201327.","journal-title":"Am J Hematol"},{"key":"615_CR4","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138.","journal-title":"Blood."},{"key":"615_CR5","doi-asserted-by":"publisher","first-page":"100640","DOI":"10.1016\/j.blre.2019.100640","volume":"40","author":"V Bachanova","year":"2020","unstructured":"Bachanova V, Perales MA, Abramson JS. Modern management of relapsed and refractory aggressive B-cell lymphoma: a perspective on the current treatment landscape and patient selection for CAR T-cell therapy. Blood Rev. 2020;40:100640.","journal-title":"Blood Rev"},{"key":"615_CR6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.clml.2019.09.598","volume":"19","author":"A Kallam","year":"2019","unstructured":"Kallam A, Vose JM. Recent advances in CAR-T cell therapy for non-Hodgkin lymphoma. Clin Lymphoma, Myeloma Leuk. 2019;19:751\u20137.","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"615_CR7","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3389\/fonc.2020.00849","volume":"10","author":"C Vitale","year":"2020","unstructured":"Vitale C, Strati P. CAR T-cell therapy for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences. Front Oncol. 2020;10:849.","journal-title":"Front Oncol"},{"key":"615_CR8","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86:10024\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"615_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","volume":"14","author":"SJC Van Der Stegen","year":"2015","unstructured":"Van Der Stegen SJC, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14:499\u2013509.","journal-title":"Nat Rev Drug Discov"},{"key":"615_CR10","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","volume":"123","author":"MV Maus","year":"2014","unstructured":"Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014;123:2625\u201335.","journal-title":"Blood."},{"issue":"5","key":"615_CR11","doi-asserted-by":"publisher","first-page":"e1049","DOI":"10.1002\/cti2.1049","volume":"8","author":"R Weinkove","year":"2019","unstructured":"Weinkove R, George P, Dasyam N, McLellan AD. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Transl Immunol. 2019;8(5):e1049.","journal-title":"Clin Transl Immunol"},{"key":"615_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/phar.2414","volume":"40","author":"CW Freyer","year":"2020","unstructured":"Freyer CW, Porter DL. Advances in CAR T therapy for hematologic malignancies. Pharmacotherapy. 2020;40:741\u201355.","journal-title":"Pharmacotherapy"},{"key":"615_CR13","doi-asserted-by":"crossref","unstructured":"Abramson JS, Lunning M, Palomba ML. Chimeric antigen receptor T-cell therapies for aggressive B-cell lymphomas: current and future state of the art. Am Soc Clin Oncol Educ B. 2019:446\u201353.","DOI":"10.1200\/EDBK_238693"},{"key":"615_CR14","doi-asserted-by":"crossref","unstructured":"Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005. p. 111\u20137.","DOI":"10.1016\/j.it.2004.12.003"},{"key":"615_CR15","doi-asserted-by":"crossref","unstructured":"Watkins MP, Bartlett NL. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas. Expert Opin. Investig. Drugs. 2018. p. 601\u201311.","DOI":"10.1080\/13543784.2018.1492549"},{"key":"615_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"\u2022\u2022 Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352 Largest clinical trial investigating efficacy and safety of liso-cell in patients with R\/R LBCL.","journal-title":"Lancet"},{"key":"615_CR17","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"\u2022\u2022 Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344 Landmark phase 2 study that led to the approval of Axi-cel in R\/R LBCL.","journal-title":"N Engl J Med"},{"key":"615_CR18","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"\u2022\u2022 Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38:3119\u201328 Real world data for standard of care Axi-Cell outside of clinical trials. Comparable effiacy and safety despite less strict patient eligbility.","journal-title":"J Clin Oncol"},{"key":"615_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"\u2022\u2022 Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell Lymphoma. N Engl J Med. 2019;380:45\u201356 Landmark phase 2 study that led to the approval of tisa-cel in R\/R LBCL.","journal-title":"N Engl J Med"},{"key":"615_CR20","doi-asserted-by":"crossref","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 2019. p. 625\u201338.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"615_CR21","unstructured":"Squibb BM. Bristol Myers Squibb provides regulatory update on lisocabtagene maraleucel (liso-cel) [Internet]. Available from: https:\/\/news.bms.com\/news\/details\/2020\/Bristol-Myers-Squibb-Provides-Regulatory-Update-on-Lisocabtagene-Maraleucel-liso-cel\/default.aspx. Accessed Dec 2020."},{"key":"615_CR22","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342.","journal-title":"N Engl J Med"},{"key":"615_CR23","unstructured":"U. S. Food and Drug Administration (FDA). FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma [Internet]. 07\/27\/2020. 2020. p. 1\u20132. Available from: https:\/\/www.fda.gov\/drugs\/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma. Accessed Dec 2020."},{"key":"615_CR24","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","volume":"4","author":"T Jain","year":"2020","unstructured":"Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4:3776\u201387.","journal-title":"Blood Adv"},{"key":"615_CR25","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","volume":"61","author":"GR Nahas","year":"2020","unstructured":"Nahas GR, Komanduri KV, Pereira D, Goodman M, Jimenez AM, Beitinjaneh A, et al. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma. 2020;61:940\u20133.","journal-title":"Leuk Lymphoma"},{"key":"615_CR26","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019;54:1643\u201350.","journal-title":"Bone Marrow Transplant"},{"key":"615_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020;26:26\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"615_CR28","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516\u201322.","journal-title":"J Clin Oncol"},{"key":"615_CR29","doi-asserted-by":"crossref","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles GA, et al. Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed\/refractory indolent non-Hodgkin lymphoma (R\/R iNHL). J Clin Oncol [Internet]. 2020;38:8008\u20138 Available from: https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2020.38.15_suppl.8008. Accessed Dec 2020.","DOI":"10.1200\/JCO.2020.38.15_suppl.8008"},{"key":"615_CR30","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood.2019000905","volume":"134","author":"AV Hirayama","year":"2019","unstructured":"Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Pender BS, et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood. 2019;134:636\u201340.","journal-title":"Blood."},{"key":"615_CR31","doi-asserted-by":"crossref","unstructured":"Geyer MB, Rivi\u00e8re I, S\u00e9n\u00e9chal B, Wang X, Wang Y, Purdon TJ, et al. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed\/refractory CLL. JCI Insight. 2019;4.","DOI":"10.1172\/jci.insight.122627"},{"key":"615_CR32","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","volume":"26","author":"NN Shah","year":"2020","unstructured":"Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020;26:1569\u201375.","journal-title":"Nat Med"},{"key":"615_CR33","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1182\/blood-2020-140907","volume":"136","author":"C Tong","year":"2020","unstructured":"Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, et al. Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma. Blood. 2020;136:1632\u201344.","journal-title":"Blood."},{"key":"615_CR34","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Munoz J, Locke FL, Miklos DB, Brown R, McDevitt JT, et al. First-in-human data of ALLO-501 and ALLO-647 in relapsed\/refractory large B-cell or follicular lymphoma (R\/R LBCL\/FL): ALPHA study. J Clin Oncol [Internet]. 2020;38:8002\u20132 Available from: https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2020.38.15_suppl.8002.","DOI":"10.1200\/JCO.2020.38.15_suppl.8002"},{"key":"615_CR35","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"\u2022\u2022 Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382:545\u201353 Phase 1 clinical trial evaluating the safety and efficacy of CD19 CAR-NK in patients with relpased CD19 lymphomas.","journal-title":"N Engl J Med"},{"key":"615_CR36","doi-asserted-by":"crossref","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020. p. 185\u201399.","DOI":"10.1038\/s41573-019-0051-2"},{"key":"615_CR37","doi-asserted-by":"crossref","unstructured":"Aftab BT, Sasu B, Krishnamurthy J, Gschweng E, Alcazer V, Depil S. Toward \u201coff-the-shelf\u201d allogeneic CAR T cells. Adv Cell Gene Ther. 2020;3.","DOI":"10.1002\/acg2.86"},{"key":"615_CR38","doi-asserted-by":"crossref","unstructured":"Kim DW, Cho JY. Recent advances in allogeneic CAR-T cells. Biomolecules. 2020.","DOI":"10.3390\/biom10020263"},{"key":"615_CR39","doi-asserted-by":"crossref","unstructured":"Hua J, Zhang J, Wu X, Zhou L, Bao X, Han Y, et al. Allogeneic donor-derived anti-CD19 CAR T Cell is a promising therapy for relapsed\/refractory B-ALL after allogeneic hematopoietic stem-cell transplantation. Clin Lymphoma, Myeloma Leuk. 2020;20:610\u20136.","DOI":"10.1016\/j.clml.2020.04.007"},{"key":"615_CR40","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","volume":"34","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Somerville RPT, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34:1112\u201321.","journal-title":"J Clin Oncol"},{"key":"615_CR41","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","volume":"122","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:4129\u201339.","journal-title":"Blood."},{"key":"615_CR42","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/bjh.14923","volume":"179","author":"Y Chen","year":"2017","unstructured":"Chen Y, Cheng Y, Suo P, Yan C, Wang Y, Chen Y, et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. Br J Haematol. 2017;179:598\u2013605.","journal-title":"Br J Haematol"},{"key":"615_CR43","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/jcm8101702","volume":"8","author":"S Sivori","year":"2019","unstructured":"Sivori S, Meazza R, Quintarelli C, Carlomagno S, Della Chiesa M, Falco M, et al. NK Cell-based immunotherapy for hematological malignancies. J Clin Med. 2019;8:1702.","journal-title":"J Clin Med"},{"key":"615_CR44","doi-asserted-by":"crossref","unstructured":"Ingegnere T, Mariotti FR, Pelosi A, Quintarelli C, De Angelis B, Tumino N, et al. Human CAR NK cells: A new non-viral method allowing high efficient transfection and strong tumor cell killing. Front Immunol. 2019;10.","DOI":"10.3389\/fimmu.2019.00957"},{"key":"615_CR45","doi-asserted-by":"crossref","unstructured":"Wang W, Jiang J, Wu C. CAR-NK for tumor immunotherapy: clinical transformation and future prospects. Cancer Lett. 2020. p. 175\u201380.","DOI":"10.1016\/j.canlet.2019.11.033"},{"key":"615_CR46","unstructured":"Clinicaltrials.gov. Website [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/home. Accessed Jan 2021."},{"key":"615_CR47","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1042\/BST20150291","volume":"44","author":"OO Yeku","year":"2016","unstructured":"Yeku OO, Brentjens RJ. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans. 2016;44:412\u20138.","journal-title":"Biochem Soc Trans"},{"key":"615_CR48","doi-asserted-by":"crossref","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019. p. 372\u201385.","DOI":"10.1038\/s41571-019-0184-6"},{"key":"615_CR49","doi-asserted-by":"crossref","unstructured":"Singh N, Orlando E, Xu J, Xu J, Binder Z, Collins MA, et al. Mechanisms of resistance to CAR T cell therapies. Semin Cancer Biol. 2020. p. 91\u20138.","DOI":"10.1016\/j.semcancer.2019.12.002"},{"key":"615_CR50","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24:1504\u20136.","journal-title":"Nat Med"},{"key":"615_CR51","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282\u201395.","journal-title":"Cancer Discov"},{"key":"615_CR52","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406\u201310.","journal-title":"Blood."},{"key":"615_CR53","doi-asserted-by":"crossref","unstructured":"Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018","DOI":"10.1038\/s41591-018-0201-9"},{"key":"615_CR54","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","volume":"16","author":"MC Jensen","year":"2010","unstructured":"Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010;16:1245\u201356.","journal-title":"Biol Blood Marrow Transplant"},{"key":"615_CR55","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563\u201371.","journal-title":"Nat Med"},{"key":"615_CR56","doi-asserted-by":"crossref","unstructured":"Das RK, Vernau L, Grupp SA, Barrett DM. Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. 2019;","DOI":"10.1158\/2159-8290.CD-18-1314"},{"key":"615_CR57","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/mt.2015.4","volume":"23","author":"KJ Curran","year":"2015","unstructured":"Curran KJ, Seinstra BA, Nikhamin Y, Yeh R, Usachenko Y, Van Leeuwen DG, et al. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther. 2015;23:769\u201378.","journal-title":"Mol Ther"},{"key":"615_CR58","doi-asserted-by":"crossref","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020.","DOI":"10.1038\/s41571-019-0297-y"},{"key":"615_CR59","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1080\/10428194.2020.1761967","volume":"61","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn K, Park JH. Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: from basic to practice. Leuk Lymphoma. 2020;61:2324\u201334.","journal-title":"Leuk Lymphoma"},{"key":"615_CR60","doi-asserted-by":"crossref","unstructured":"Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020","DOI":"10.1182\/bloodadvances.2020002394"},{"key":"615_CR61","doi-asserted-by":"crossref","unstructured":"Zhang E, Xu H. A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. J. Hematol. Oncol. 2017.","DOI":"10.1186\/s13045-016-0379-6"},{"key":"615_CR62","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/j.bbmt.2019.12.771","volume":"26","author":"P Dreger","year":"2020","unstructured":"Dreger P, Fenske TS, Montoto S, Pasquini MC, Sureda A, Hamadani M. Cellular immunotherapy for refractory diffuse large B cell lymphoma in the chimeric antigen receptor-engineered T cell era: still a role for allogeneic transplantation? Biol Blood Marrow Transplant. 2020;26:e77\u201385.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00615-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-021-00615-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00615-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T19:35:53Z","timestamp":1618947353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-021-00615-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1007\/s11899-021-00615-7","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"10 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}